Month: September 2026
-
Ratio Therapeutics Announces the Appointment of Kenan Turnacioglu to its Board of Directors
BOSTON, MA September 17, 2026 — Ratio Therapeutics Inc. (“Ratio”) a clinical-stage pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced the appointment of Kenan Turnacioglu, Ph.D., to its Board of Directors. Dr. Turnacioglu brings more than two decades of experience spanning healthcare investing, biotechnology company building, oncology and corporate…
-
Ratio Therapeutics Enters into Research Collaboration and License Agreement with RayzeBio to Advance a Novel Radiopharmaceutical Program
Collaboration brings together complementary expertise and proprietary technologies to advance a next-generation radiopharmaceutical candidate with the potential to enhance tumor targeting. BOSTON, MA, September 9, 2026 – Ratio Therapeutics Inc. (Ratio), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment, today announced that it has entered into a research collaboration and…